Status
Announced
Official links
- Draft prospectusDRHP means the draft prospectus. It describes the company before the price and the dates are fixed.
How to apply
Use UPI and ASBA. The guide covers the close, allotment, and the T+3 listing.
Open the guideRelated guides
Aragen Life Sciences Ltd. IPO is announced. The offer is a fresh issue of ₹800 crore. In FY26, total income was ₹2,225.59 crore and profit after tax was ₹257.64 crore. Total income was up 19% from ₹1,870.29 crore in FY25. Profit after tax was up 42.8% from ₹180.38 crore in FY25.
Aragen Life Sciences Ltd. is at the draft prospectus stage. A DRHP is the draft red herring prospectus a company files before a public issue opens. It describes the business, the promoters, and how any fresh money would be used. It does not set the price band, the lot size, or the dates. Those are fixed later, in the red herring prospectus.
What to watch next for Aragen Life Sciences Ltd. is the opening date, the closing date, the price band, and the lot size. This page will list each figure only after it is announced. It will not guess a price, a date, or a grey market premium. Until those details are out, read the draft prospectus if this page links to it. Check who the promoters are and what the company says the money is for. When the dates are published, the timeline here will show the open, the close, allotment, refunds, the credit to your demat account, and the listing.
Aragen Life Sciences is a contract research, development and manufacturing company (CRDMO). It works for pharmaceutical and biotechnology companies around the world.
Dates
Opens
TBA
Closes
TBA
AllotmentAllotment is the decision of who gets shares after the issue closes. Basis of allotment, in the glossary
TBA
Refunds
TBA
Demat credit
TBA
Listing
TBA
Objects of the issue
- Repayment and/or pre-payment, in part or full of certain borrowings availed by the Company and Material Subsidiaries
- Capital expenditure to be incurred by the Company for purchase of new equipment and machinery for the facilities in Hyderabad
- Capital expenditure to be incurred by one of our Material Subsidiaries, namely Aragen Biologics Private Limited for purchase of new equipment and machinery for the facility in Bengaluru, Karnataka
- General corporate purposes
Promoters
Davinder Singh Brar, Reddy Investment Trust, Madhubani Investments Pvt.Ltd., Aparna Reddy Gunapati and Keshav Gunupati Venkat Reddy
Issue structure
Fresh issue
₹800 crore
Issue
- Face value
- ₹10
- Fresh issue
- ₹800 crore
- Exchanges
- BSE, NSE
- Registrar
- Kfin Technologies Ltd.
Financials
₹ crore, for the last three reported years.
Total income and profit
Each chart has its own scale. Amounts are in ₹ crore.
Total income
Profit after tax
| Year | Total income | Profit |
|---|---|---|
| FY24 | ₹1,674.68 crore | ₹160.1 crore |
| FY25 | ₹1,870.29 crore | ₹180.38 crore |
| FY26 | ₹2,225.59 crore | ₹257.64 crore |
Net worth
₹ crore, for each year that reports net worth.
| Year | Net worth |
|---|---|
| FY24 | ₹1,295.4 crore |
| FY25 | ₹2,058.8 crore |
| FY26 | ₹2,308.31 crore |
| Year | Total income | PAT | Net worth | Assets | Borrowings |
|---|---|---|---|---|---|
| FY24 | 1,674.68 | 160.1 | 1,295.4 | — | — |
| FY25 | 1,870.29 | 180.38 | 2,058.8 | — | — |
| FY26 | 2,225.59 | 257.64 | 2,308.31 | — | — |
Frequently asked questions
What is the issue size?
The offer is a fresh issue of ₹800 crore.
Where is the DRHP?
The DRHP for Aragen Life Sciences Ltd. is linked on this page.
This page is a calendar of dates and prices. It is not a recommendation to apply.